Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.37 +0.09 (+0.19%)
Streaming Delayed Price Updated: 1:41 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
31 32 Next >
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study
Via Benzinga
SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories
Benzinga 
Via Benzinga
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
These two companies are showering shareholders with market-topping payouts. 
Via The Motley Fool
Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi
Via Benzinga
Why Provention Bio Stock Skyrocketed 256% This Week
Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker. 
Via The Motley Fool
What's Going On With Sanofi Stock After Hours?
Sanofi SA (NASDAQ: SNY) is buzzing in Thursday's after-hours session after the company said it will cut the list price of its most widely prescribed insulin in the United States  
Via Benzinga
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
On a volatile market day, companies are still looking for smart combinations. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
How Is The Market Feeling About Sanofi?
Via Benzinga
FDA Approves Sanofi's Hemophilia A Therapy Offering Significant Bleed Protection
Via Benzinga
Sanofi (SNY) Q4 2022 Earnings Call Transcript
SNY earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion
Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal
Pfizer expects Seagen to add at least $10 billion to its topline in 2030. 
Via Investor's Business Daily
Why Provention Bio Stock Is Rocketing Past 52-Week Highs Today
Provention Bio Inc (NASDAQ: PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ: SNY) announced plans to acquire the biopharmaceutical company. 
Via Benzinga
Why Is Provention Bio (PRVB) Stock Up 263% Today?
Provention Bio (PRVB) stock is rocketing higher on Monday following news that Sanofi (SNY) is acquiring the company for $2.9 billion. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday! 
Via InvestorPlace
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis. 
Via Benzinga
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
These companies aren't working on a vaccine, but a monoclonal antibody. 
Via Investor's Business Daily
7 Blue-Chip Stocks to Buy for Quality-Focused Investors
With circumstances shaky in the market right now, concerned investors may want to consider blue-chip stocks to buy. 
Via InvestorPlace
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
The French drug company got the nod for a hemophilia treatment. 
Via The Motley Fool
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
Via Benzinga
Eli Lilly Slashes Insulin Prices By 70%, Will Other Insulin Makers Follow Suit?
Eli Lilly & Co (NYSE: LLY), in an effort to make it easier for patients to access affordable insulin and navigate the complex healthcare system, announced on Wednesday a 70% reduction in the list price... 
Via Benzinga
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
Shares crumbled after Moderna's flu shot outperformed in just one flu strain. 
Via Investor's Business Daily
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony... 
Via Benzinga
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report. 
Via Investor's Business Daily
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.